Screener
Xenon Pharmaceuticals XENE EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Xenon Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
FAQ
- What is Xenon Pharmaceuticals's EBITDA margin?
- Xenon Pharmaceuticals (XENE) reported EBITDA margin of -4,940.4% in Q4 2025.
- What is the long-term trend for Xenon Pharmaceuticals's EBITDA margin?
- Over 3 years (2020 to 2025), Xenon Pharmaceuticals's EBITDA margin has grown at a 272.9% compound annual growth rate (CAGR), from -95.3% to -4,940.4%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Xenon Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude